目的 觀察復(fù)方萬年青膠囊聯(lián)合SOX化療方案（奧沙利鉑和替吉奧）治療晚期胃癌的臨床療效。方法 選擇2018年3月—2021年2月中國人民武裝警察部隊河南省總隊醫(yī)院收治的107例晚期胃癌患者，根據(jù)隨機數(shù)字表法分為對照組（53例）和治療組（54例）。對照組采用SOX化療方案治療。第1天靜脈滴注注射用奧沙利鉑，130 mg/(m²·d)，10%葡萄糖注射液500 mL稀釋，靜滴3 h，隔21 d治療1次；同時當(dāng)天溫水送服替吉奧膠囊，80 mg/(m²·d)，2次/d，連續(xù)14 d，停藥7 d。治療組在對照組基礎(chǔ)上溫水送服復(fù)方萬年青膠囊，3粒/次，3次/d。兩組均以21 d為1個治療周期，連續(xù)治療3個周期。觀察兩組療效，比較兩組生存質(zhì)量、血清腫瘤標(biāo)志物水平。結(jié)果 治療后，治療組的臨床總有效率（50.00%）、疾病控制率（85.19%）均高于對照組（30.19%、58.49%），組間對比差異有統(tǒng)計學(xué)意義（P＜0.05）。治療后，兩組認(rèn)知功能、角色功能、軀體功能、情緒功能、社會功能評分均顯著升高（P＜0.05）；且治療組認(rèn)知功能、角色功能、軀體功能、情緒功能、社會功能評分均顯著高于對照組（P＜0.05）。治療后，兩組血清腫瘤相關(guān)物質(zhì)群（TSGF）、糖類抗原-199（CA-199）、癌胚抗原（CEA）、糖鏈抗原724（CA724）水平均下降（P＜0.05）；且治療組血清TSGF、CA-199、CEA、CA724水平低于對照組（P＜0.05）。結(jié)論 復(fù)方萬年青膠囊聯(lián)合SOX化療方案治療晚期胃癌可提高患者生活質(zhì)量，降低血清腫瘤標(biāo)志物水平，減少不良反應(yīng)。

Objective To observe the clinical efficacy of Compound Wannianqing Capsules combined with SOX chemotherapy regimen in treatment of advanced gastric cancer.Methods Patients (107 cases) with advanced gastric cancer in Henan Corps Hospital of the Chinese People's Armed Police Force from March 2018 to February 2021 were randomly divided into the control group (53 cases) and the treatment group (54 cases). Patients in the control group were given SOX chemotherapy regimen. Patients in the control group were iv administered with Oxaliplatin for injection at the first day, 130 mg/(m²·d) added into 10% glucose injection 500 mL, intravenous drip for 3 h, once every 21 d. Meanwhile patients in the control group were po administered with Tegafur, Gimeracil and Oteracil Potassium Capsules, twice daily, continuous treatment for 14 d, and drug withdrawal for 7 d. Patients in the treatment group were po administered with Compound Wannianqing Capsules on the basis of the control group, 3 grains/time, three times daily. Taking 21 d as a treatment cycle, patients in two groups were treated for 3 cycles. After treatment, the clinical efficacies were evaluated, and the quality of life and serum levels of tumor markers in two groups were compared.Results After treatment, the total clinical effective rate (50.00%) and disease control rate (85.19%) in the treatment group were higher than those in the control group (30.19% and 58.49%), and there was significant difference between the groups (P < 0.05). After treatment, the scores of cognitive function, role function, somatic function, emotional function, and social function in two groups were increased (P < 0.05), and the scores of cognitive function, role function, somatic function, emotional function, and social function in the treatment group were higher than those in the control group (P < 0.05). After treatment, the serum levels of TSGF, CA-199, CEA, and CA724 in two groups were decreased (P < 0.05), and the serum levels of TSGF, CA-199, CEA, and CA724 in the treatment group were lower than those in the control group (P < 0.05).Conclusion Compound Wannianqing Capsules combined with SOX chemotherapy regimen in treatment of advanced gastric cancer can improve the quality of life, reduce the serum level of tumor markers, and reduce the incidence of adverse reactions.

R979.1

河南省醫(yī)學(xué)科技攻關(guān)計劃聯(lián)合共建項目（LHGJ20190428）